197 related articles for article (PubMed ID: 16645226)
1. T-cell prolymphocytic leukemia.
Dearden CE
Med Oncol; 2006; 23(1):17-22. PubMed ID: 16645226
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia.
Tuset E; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
Leuk Lymphoma; 2001; 42(6):1379-83. PubMed ID: 11911422
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
[TBL] [Abstract][Full Text] [Related]
4. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
5. How I treat prolymphocytic leukemia.
Dearden C
Blood; 2012 Jul; 120(3):538-51. PubMed ID: 22649104
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab in peripheral T-cell malignancies.
Dearden C
Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953
[TBL] [Abstract][Full Text] [Related]
7. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
[TBL] [Abstract][Full Text] [Related]
8. High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia.
Costa D; Queralt R; Aymerich M; Carrió A; Rozman M; Vallespí T; Colomer D; Nomdedeu B; Montserrat E; Campo E
Cancer Genet Cytogenet; 2003 Nov; 147(1):36-43. PubMed ID: 14580769
[TBL] [Abstract][Full Text] [Related]
9. Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization.
Maljaei SH; Brito-Babapulle V; Hiorns LR; Catovsky D
Cancer Genet Cytogenet; 1998 Jun; 103(2):110-6. PubMed ID: 9614908
[TBL] [Abstract][Full Text] [Related]
10. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
11. 14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia.
Kojima K; Kobayashi H; Imoto S; Nakagawa T; Matsui T; Kawachi Y; Oda K; Yano T; Kobayashi H; Noguchi M; Hara M; Oshimi K
Int J Hematol; 1998 Oct; 68(3):291-6. PubMed ID: 9846013
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival in two cases of T-prolymphocytic leukemias with complex hypodiploid chromosomal abnormalities.
Yokohama A; Karasawa M; Takada S; Matsushima T; Murakami H; Miyao S; Sato S; Naruse T
J Med; 2000; 31(3-4):183-94. PubMed ID: 11280450
[TBL] [Abstract][Full Text] [Related]
13. Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders?
Delgado J; Bustos JG; Jimenez MC; Quevedo E; Hernandez-Navarro F
Leuk Lymphoma; 2002 Dec; 43(12):2331-4. PubMed ID: 12613520
[TBL] [Abstract][Full Text] [Related]
14. Trisomy 8q due to i(8q) or der(8) t(8;8) is a frequent lesion in T-prolymphocytic leukaemia: four new cases and a review of the literature.
Mossafa H; Brizard A; Huret JL; Brizard F; Lessard M; Guilhot F; Tanzer J
Br J Haematol; 1994 Apr; 86(4):780-5. PubMed ID: 7918072
[TBL] [Abstract][Full Text] [Related]
15. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
16. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia.
Brito-Babapulle V; Catovsky D
Cancer Genet Cytogenet; 1991 Aug; 55(1):1-9. PubMed ID: 1913594
[TBL] [Abstract][Full Text] [Related]
17. T-cell prolymphocytic leukemia with hemorrhagic gastrointestinal involvement and a new chromosomal abnormality.
Toyota S; Nakamura N; Dan K
Int J Hematol; 2002 Apr; 75(3):314-7. PubMed ID: 11999363
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
[TBL] [Abstract][Full Text] [Related]
19. Seropositive polyarthritis and skin manifestations in T-prolymphocytic leukemia/Sezary cell leukemia variant.
Dybjer A; Hellquist L; Johansson B; Rydgren L; Billström R
Leuk Lymphoma; 2000 Apr; 37(3-4):437-40. PubMed ID: 10752996
[TBL] [Abstract][Full Text] [Related]
20. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group.
Döhner H; Ho AD; Thaler J; Stryckmans P; Sonneveld P; de Witte T; Lechner K; Lauria F; Bödewadt-Radzun S; Suciu S
J Natl Cancer Inst; 1993 Apr; 85(8):658-62. PubMed ID: 8468724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
